YOKOHAMA, Japan, Nov. 28, 2025 /PRNewswire/ -- The Yokohama Renaissance Project Council (YRP Council) has launched the "Yokohama Silk Renaissance," an initiative that reinterprets the city's historic silk heritage for today's global MICE and luxury tourism markets. Yokohama, long known as Japan's largest raw silk export port during the Meiji era, seeks to elevate this legacy into a contemporary cultural brand with strong international appeal. Tourism Media Service spoke with the organizer about this unique program.
Repositioning Yokohama's Silk Heritage for Global MICE and High-Value Tourism
The project introduces five categories of experiential content—Silk Reception, Silk Dining, Silk & Flower Craft, Silk Fashion, and Silk Performance—developed in collaboration with luxury hotels, restaurants, artisans, and cultural organizations. With a rising number of international conferences at PACIFICO Yokohama and increased cruise arrivals at Shinko Pier, the initiative targets the growing global demand for premium cultural programs as part of corporate hospitality, incentive travel, and VIP guest experiences.
These programs aim to provide high-spending visitors with curated cultural engagement, aligning the city's historical assets with international market trends and reinforcing Yokohama's position as a competitive MICE destination in East Asia.
Silk Reception Debuts as a Flagship Program for Corporate Hospitality
The first major showcase, Silk Reception, debuted on October 6, 2025, at "Aperitif 2025." The program highlighted Yokohama's cultural depth through:
- Silk painting and pressed flower workshops
- A new silk fashion presentation by designer Michiyo Inaba
- A collaborative performance by Yokohama and Hachioji geisha, historically linked through Japan's silk trade
- Silk-inspired gastronomy crafted by chefs from the Yokohama Gastronomy Council
Tourism professionals, corporate planners, and global event organizers responded positively, emphasizing the program's strong suitability for VIP receptions and MICE events. Many attendees highlighted the unique fusion of traditional performing arts, silk craftsmanship, and contemporary design as a compelling differentiator for international markets.
Expanding Premium Cultural Offerings Toward GREEN×EXPO 2027
In anticipation of GREEN×EXPO 2027 (the 2027 International Horticultural Expo), the initiative will expand its "Flowers & Silk" programs, connecting Yokohama's nature, history, and culture into integrated visitor experiences. Planned developments include:
- VIP reception and corporate hospitality packages for MICE planners
- Shore excursion options for luxury cruise passengers
- Collaborative accommodation programs with Yokohama's high-end hotels
- Regional cultural routes linking Yokohama with Hachioji, Tomioka Silk Mill, and other sites along the historic "Yokohama Silk Road"
These efforts aim to enhance the consistency and marketability of Yokohama's cultural brand to high-value international audiences.
Toward a Distinctive Global Cultural Brand
"Silk is an iconic cultural asset that shaped Yokohama's modernization," the YRP Council stated. "By transforming its historical value into contemporary experiences, we seek to establish a distinctive cultural brand that resonates across global tourism and MICE markets."
The Yokohama Silk Renaissance is gaining attention across the industry as Yokohama positions itself as a leading cultural destination for high-value international travelers and business events.
Reservations / Media Inquiries
Yokohama Renaissance Project Council (YRP Council)
Official Website (JP): https://yokohamadmc.com/yokohama_silk/jp.html
Official Website (EN): https://yokohamadmc.com/yokohama_silk/
Email: info@yokohamadmc.com
Media Contact:
Tetsuro Yamamura, President & CEO, Yokohama DMC (YDMS Inc.)
- About Tourism Media Service:
An online news platform specializing in the tourism industry. It provides the latest news on regional development and travel information, as well as feature articles on topics such as trends and observations, contributed by over 100 experts, every day.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Yokohama Revitalizes Its Historic Silk Culture with "Yokohama Silk Renaissance" for Global Luxury and MICE Markets
SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. The evening, co-hosted by Founding Platinum Sponsor Wilson Sonsini and the BayHelix Group, recognized outstanding achievements in healthcare investment, financing, and deal-making over the past year.
This year's awards honored the companies and individuals at the forefront of China's dynamic healthcare sector — from landmark licensing and partnership agreements to capital markets milestones and private financings that are reshaping the industry. Award recipients were selected through a formal vote conducted by CHIC's Founders and 2026 Organizing Committee & Working Group, whose collective expertise spans venture capital, private equity, and global healthcare leadership.
Award Winners
IPO of the Year
Winner: Insilico Medicine
Accepted by: Leah Liu, VP and Global Head of IR & Capital Markets, Insilico Medicine
Presenter: Richard Wang, China Partner, Wilson Sonsini
Private Financing of the Year — Tied
Co-Winner: Kailera Therapeutics
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui (Kailera Therapeutics was built on Hengrui assets)
Presenter: Kan Chen, Co-Head of Healthcare, Qiming Venture Partners
Co-Winner: Vor Bio
Accepted by: Jianmin Fang, CEO, RemeGen (Vor Bio's leading project is from RemeGen)
Presenter: Cyber Cao, Managing Director, HSG
Deal of the Year — Tied
Co-Winner: Hengrui Pharma – GSK
Accepted by: Shelley Liu, Head of China Business Development & Strategy, Hengrui; and Ming Fang, PhD, Senior Director, Search & Evaluation, Business Development, GSK
Presenter: Steve Yang, Co-Founder, the BayHelix Group; Co-CEO, WuXi Apptec
Co-Winner: Innovent – Takeda
Accepted by: Sophy Wang, Board Secretary & Global BD, Innovent; and Eric Yeung, Head of Oncology and Global Business Development, Takeda
Presenter: Kevin Yuan, CEO, Hankang Capital
About CHIC 2026
The China Healthcare Investment Conference (CHIC) is a premier platform connecting innovation and investment in China's healthcare sector. Now in its 12th year, CHIC brings together senior decision-makers including venture capital and private equity investors, pharmaceutical executives, and biotech and medtech CEOs. The 2026 conference was held on March 23–24 at The Ritz-Carlton Hotel Pudong, Shanghai, under the theme "Innovation in Healthcare – The Answer to Uncertainty."
About the Gala Dinner Co-Hosts
Wilson Sonsini is a leading legal advisor to life sciences, and biotechnology industries, offering integrated counsel across the full spectrum of a company's life cycle — from early-stage intellectual property strategy and patent prosecution to complex technology transactions, licensing, collaborations, as well as M&As, IPOs and capital market offerings. As Founding Platinum Sponsor of CHIC, Wilson Sonsini has been a steadfast partner in the conference's mission to connect healthcare innovation with global capital.
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix serves as a co-host of the CHIC Gala Dinner and is a longstanding partner in advancing the global development of China's healthcare sector.
CHIC 2026 Founding Individuals & Organizing Committee / Working Group
The following individuals served as the voting body for the CHIC 2026 Awards, representing the CHIC Founding Individuals and the Organizing Committee & Working Group.
Founders
Marietta Wu, Managing Director, Quan Capital
Frank Kung, Managing Partner, Vivo Capital
Hongbo Lu, Managing Member, NEXTBio Capital
James Li, Venture Partner, Frazier Lifesciences
Norman Chen, CEO, The Asian American Foundation
2026 Organizing Committee & Working Group
Cyber Cao, Managing Director, HSG
Jialing Dai, President & Publisher, PharmaDJ
Tess Cameron, Managing Director, RA Capital Management
Kan Chen, Co-Head of Healthcare, Qiming Venture Partners
Sean Zhang, Executive Director, Vivo Capital
Dandan Dong, Venture Partner, TCGX
Anna Chen, Partner, Frazier Life Sciences
Yuan Yuan, Head of Platform Development, China, NEXTBio Capita
Zhanghang Yan, Vice President, Quan Capital
Yun Gao, Principal, Lilly Asia Ventures
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala
